Integrated Treatment for Mental Illness and Substance Use Disorders

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Integrated treatment addresses a substance use disorder and a co-occurring mental disorder within one coherent clinical plan. The patient receives assessment, treatment decisions, safety planning, and continuing follow-up that explicitly account for both conditions. Care may be delivered by one interdisciplinary team, by clinicians working together in the same service, or through reliably coordinated services. Its defining feature is the active integration of clinical decisions: changes in substance use inform mental health treatment, mental health symptoms inform addiction treatment, and responsibility for continuity is clear. The approach applies to combinations such as alcohol use disorder and depression, opioid use disorder and posttraumatic stress disorder, bipolar disorder and stimulant use disorder, or schizophrenia and cannabis use disorder. SAMHSA TIP 42 and the SAMHSA co-occurring disorders guidance provide the principal service framework.

The clinical purpose is to reduce preventable harm, improve engagement and functioning, and deliver evidence-based treatment for each established disorder without making recovery from one a prerequisite for care of the other. Integrated treatment has substantial professional and guideline support. The estimated added effects of particular integrated psychotherapies, however, vary across diagnoses, comparators, outcomes, and study quality. A 2025 meta-analysis covering 47 randomized trials found modest and comparison-dependent effects of cognitive-behavioral interventions for co-occurring substance and mental health disorders. Magill et al., 2025.

What Are Co-Occurring Mental Illness and Substance Use Disorders?

The term co-occurring disorders describes the presence of at least one diagnosable mental disorder and at least one diagnosable substance use disorder in the same person. The clinical formulation must establish that each condition meets its respective criteria. A person who experiences anxiety during acute stimulant intoxication or low mood during alcohol withdrawal requires assessment, but those symptoms alone do not establish a second independent psychiatric diagnosis. Conversely, symptoms that began before substance exposure, continue beyond expected substance effects, recur in periods of sustained remission, or form a characteristic longitudinal syndrome may support an independent mental disorder. SAMHSA TIP 42, Chapter 4.

Substance use means consuming alcohol or another psychoactive substance. Risky use describes patterns associated with increased likelihood of harm; problematic or harmful use describes consequences that warrant clinical attention. Substance use disorder is a defined diagnostic syndrome involving impaired control and clinically meaningful impairment or distress. Addiction refers to the compulsive, persistently harmful pattern often associated with more severe forms of a substance use disorder. Physiological dependence, tolerance, and withdrawal are distinct pharmacological or physiological phenomena and can occur during properly supervised medication treatment without proving addiction. These distinctions determine which problems a care team must diagnose and which risks it must manage.

A mental disorder may involve depression, bipolar mood episodes, PTSD, an anxiety disorder, schizophrenia-spectrum illness, obsessive-compulsive disorder, ADHD, or another clinically established syndrome. The relevant assessment addresses symptom severity, history, functioning, suicide risk, cognition, social context, and the effects of medications and substances. Comprehensive care also recognizes pain, infectious disease, sleep disruption, trauma exposure, housing insecurity, and barriers to accessing services. SAMHSA TIP 42, Chapters 2–3.

Why co-occurrence changes treatment

Symptoms, exposures, and treatment responses interact over time. Alcohol can worsen sleep, mood, and anxiety; withdrawal can resemble or intensify psychiatric symptoms. Stimulant use can coincide with agitation, insomnia, psychotic experiences, and cardiovascular toxicity. Trauma-related hyperarousal may increase the urge to use substances as a short-term coping strategy. Mania can increase impulsivity, exposure to substances, and interrupted medication use. Sedating medicines and alcohol or opioids may combine to increase respiratory risk. The strength and direction of these relationships are individual and require evaluation rather than assumptions about a single causal pathway.

Shared genetic liability, adverse experiences, environmental exposure, altered reward learning, negative reinforcement, social stress, and disruptions in executive regulation can contribute to co-occurrence. At the same time, correlations between disorders cannot establish that one caused the other. Treatment planning benefits from documenting the actual chronological sequence of symptoms, use patterns, prior treatment, and periods of relative stability. The SAMHSA clinical framework places longitudinal understanding and repeated reassessment at the center of care.

Integrated, Coordinated, and Sequential Treatment

A sequential model treats one condition first and addresses the second at a later stage. A parallel model delivers both treatments during the same period through largely separate programs. Coordinated care retains distinct services but establishes communication, shared goals, and referral accountability. Co-located care makes both services available at one site. Fully integrated care combines expertise, treatment planning, and monitoring within one program or closely functioning clinical team. SAMHSA, Managing Life With Co-Occurring Disorders.

These models describe how services are organized; they do not by themselves identify the best psychological treatment for every patient. A patient attending an opioid treatment clinic and a trauma-focused outpatient service may receive excellent concurrent care if both teams know the shared plan and coordinate safety and follow-up. One building and one electronic record do not ensure integration if the substance use and psychiatric teams make contradictory decisions. Practical integration becomes visible when diagnoses are reconsidered together, medicines are reconciled, worsening symptoms prompt a timely response, and a missed appointment results in outreach rather than loss of access.

Certain acute conditions require an immediate medical priority. Suspected opioid overdose, severe alcohol or sedative withdrawal, delirium, psychosis with dangerous behavior, acute mania with serious impairment, or imminent suicide risk demand urgent assessment and stabilization. This is compatible with integrated longitudinal treatment: emergencies are managed according to clinical severity while a plan for both disorders is maintained. The NICE guidance on psychosis and coexisting substance misuse calls for active assessment, coordinated care, and access to both services.

How Integrated Treatment Begins: Screening and Assessment

Two-way screening at every appropriate entry point

People entering addiction care should be screened for common mental health concerns; people entering mental health care should be asked about alcohol, prescribed medicines, nicotine, cannabis, opioids, stimulants, and other substances. Screening instruments identify possible conditions and the need for further clinical assessment. A positive screen is not a diagnosis. Frequency or quantity questions, symptom questionnaires, medication histories, and validated disorder-specific measures can clarify which topics require evaluation. Screening must be adapted to developmental stage, language, cognitive state, and current medical stability. SAMHSA TIP 42; SAMHSA 2024 advisory.

A comprehensive assessment establishes the substances used, route and pattern of exposure, intoxication and withdrawal history, overdose history, treatment history, prescription and nonprescription medicines, psychiatric episodes, trauma history when appropriate, past self-harm or suicidality, sleep, physical illness, social supports, and access to housing and transportation. Clinicians review strengths, treatment preferences, and the person's own goals. With consent and when useful, family or other collateral accounts can help reconstruct episodes affected by intoxication, psychosis, or impaired recall. The NICE CG120 recommendations emphasize multidisciplinary assessment and reassessment over time.

Independent disorder or substance-induced presentation?

Distinguishing an independent psychiatric disorder from a substance-induced condition is a longitudinal task. The clinician examines whether symptoms arose during use, intoxication, withdrawal, medication changes, or sleep deprivation; whether comparable episodes appeared before substance exposure; whether symptoms persist at a clinically meaningful interval; and whether other medical explanations fit. Several conditions can coexist: a person with schizophrenia may also experience substance-induced exacerbations, and someone with major depression may have transient withdrawal-related dysphoria. Diagnostic confidence may increase with time and documented observation. Care and safety should proceed while uncertainty is clinically managed.

The diagnostic formulation should record what is established, what remains provisional, and which observations would change a diagnosis. A team must not interpret every symptom in a person using substances as caused by substance use, nor automatically treat every distressing symptom as evidence of a separate disorder. The specific differentiation between a primary and substance-induced psychotic syndrome belongs to Substance-Induced Psychosis: Causes, Symptoms, and Treatment.

Safety assessment before and during treatment

Urgent assessment includes consciousness, breathing, vital signs, acute poisoning, withdrawal complications, psychosis, severe mood disturbance, and suicidal thoughts or behavior. Clinicians assess access to potentially lethal means, prior attempts, intoxication-related disinhibition, and ability to remain safe. Harm reduction and crisis arrangements are individualized. Someone with slow or absent breathing, unresponsiveness, a seizure, severe confusion, chest pain associated with stimulant use, or immediate danger to self or others needs emergency medical help. For suspected opioid overdose, emergency services and naloxone where available are indicated; naloxone does not replace emergency care. CDC: Treating Opioid Use Disorder.

Alcohol and benzodiazepine withdrawal can produce seizures and delirium and may be life-threatening; dependent patients require medically guided decisions about withdrawal management. A patient should not receive a self-directed abrupt discontinuation or rapid-taper plan from educational information. Pregnancy, complicated medical illness, significant polysubstance exposure, and a history of severe withdrawal change the level of monitoring required. Stabilization, medically supervised withdrawal management, and long-term disorder treatment are related but distinct components of care.

An Individualized Treatment Plan for Two Conditions

A workable integrated plan names both diagnoses or provisional clinical formulations and links them to measurable goals. It specifies who manages psychiatric medications, who provides substance-specific treatment, who reviews potential drug interactions, who handles acute crises, and who contacts the patient after missed visits or discharge. The patient should be able to describe the next appointment, medicines and safety plan, and whom to contact when symptoms worsen. SAMHSA TIP 42, Chapter 7.

Initial goals may include relief of withdrawal or intoxication, protection against overdose, starting indicated medication, stabilizing psychosis or mania, restoring sleep, securing housing, reducing substance-related injury, or building a therapeutic relationship. Subsequent goals may concern sustained changes in substance use, remission of mood or trauma symptoms, social functioning, work, parenting, or quality of life. The plan should include the person's preferences concerning abstinence, reduced use where clinically appropriate, and the relative priority of different outcomes. Patient choice operates alongside careful explanation of medical risks, including circumstances where any continued use is particularly hazardous.

Integrated care can organize the work in phases without postponing all mental health care until a fixed abstinence milestone. Engagement establishes safety and trust; active treatment targets symptoms and harmful substance use; longer-term care addresses recurrence prevention and functioning. Stages overlap and are revisited as circumstances change. SAMHSA describes a recovery orientation, a multidimensional problem perspective, phased treatment, practical problem-solving, cognitive accommodations, and durable support systems as organizing principles. SAMHSA TIP 42, Chapter 2.

Shared decision-making and the therapeutic relationship

People may arrive after repeated refusals, fragmented referrals, insurance barriers, or stigmatizing encounters. Explaining clinical uncertainty, validating individual treatment priorities, and explicitly connecting the two areas of care improves the conditions for engagement. Motivational interviewing can help explore ambivalence without coercion. Collaborative planning should account for cognitive limitations, acute stress, language, culture, disability, privacy, and previous experiences of services. Collaboration does not erase professional obligations to act when a dangerous medical or psychiatric emergency is present.

Medication Treatment Within an Integrated Plan

Medication selection follows the evidence and clinical indications for each diagnosed condition. The goal is to treat substance use disorder and psychiatric illness competently while accounting for interactions, adherence, organ function, pregnancy status, overdose risk, and effects on sleep and cognition. Integrated care is not a distinctive pill regimen. Medication review is especially important when several prescribers, substances, and pharmacies are involved. NICE CG120.

Opioid use disorder and co-occurring psychiatric illness

Buprenorphine and methadone are established medications for opioid use disorder. Extended-release naltrexone is an option for selected patients after appropriate clinical evaluation and opioid-free transition. Long-term OUD treatment must be distinguished from managing a withdrawal episode. Co-occurring depression, PTSD, anxiety, or psychosis should prompt concurrent assessment and care, while access to evidence-based OUD medication remains a clinical priority. The 2020 ASAM guideline states that declining psychosocial services should not delay appropriate OUD pharmacotherapy. ASAM National Practice Guideline; CDC OUD clinical guidance.

A shared prescriber or team must consider additive sedation from alcohol, benzodiazepines, and other central nervous system depressants. Many patients nonetheless benefit from coordinated treatment of both conditions, including indicated psychiatric medications. Decisions about medication changes or monitoring belong to qualified clinicians and should avoid sudden changes that create withdrawal, psychiatric destabilization, or return-to-use risks. The full substance-specific evidence is addressed in Opioid Use Disorder: Symptoms, Risks, and Treatment.

Alcohol use disorder and mental illness

Naltrexone and acamprosate have established roles in alcohol use disorder treatment in appropriately selected patients; disulfiram has a more limited and adherence-dependent role. Medication choice depends on the person's treatment goal and medical contraindications, including hepatic or renal considerations and current opioid use. Co-occurring depression or anxiety requires its own assessment and indicated treatment. Withdrawal risk, malnutrition, cognitive problems, and alcohol-medication interactions may shape the setting and sequencing of interventions. Alcohol withdrawal treatment alone does not complete treatment for alcohol use disorder. NIAAA: Treatment for Alcohol Problems.

Stimulants, cannabis, nicotine, and other substances

The treatment options differ by substance. For stimulant use disorders, behavioral approaches and contingency management have the strongest relevant psychosocial evidence, with additional decisions based on the patient's clinical situation; pharmacological strategies under study must be distinguished from established medications for OUD or alcohol use disorder. Tobacco cessation medications and behavioral support can be provided as part of psychiatric and addiction services. People with psychosis, severe anxiety, or bipolar disorder need monitoring for intoxication-related symptoms and for changing sleep and mood during reductions in substance use. ASAM and AAAP Clinical Practice Guideline on Stimulant Use Disorder; How to Quit Smoking: Effective Medications and Behavioral Support.

Psychiatric medicines and therapeutic caution

Antidepressants, antipsychotics, mood stabilizers, and other psychiatric treatments may be indicated under disorder-specific guidance; evidence for one psychiatric diagnosis does not establish treatment of the associated addiction. Prescribers reassess side effects, interactions, adherence, and the effects of substance use on mental state and medication response. Shared medical records, deliberate prescription reconciliation, and clear communication about sedating agents reduce avoidable fragmentation. The therapeutic objective is stable, supervised, condition-specific treatment, with timely revisions when evidence changes.

Psychological and Behavioral Therapies

Cognitive behavioral therapy can address the interaction of cravings, emotions, beliefs, avoidance, sleep, exposure to cues, and relapse-risk situations. Integrated cognitive-behavioral approaches combine these elements with strategies appropriate to the diagnosed mental disorder. Motivational interviewing addresses readiness and engagement; contingency management reinforces specified recovery-related behaviors. Family work, skills training, supported employment, and case management may address functional and contextual needs. None of these approaches has identical evidence across all substance and mental health diagnoses.

The largest recent quantitative synthesis in this area examined 47 randomized trials of cognitive-behavioral interventions for alcohol or other drug use and co-occurring mental health disorders, including 5,535 individuals. Compared with control or usual-care conditions, the interventions showed advantages for substance consumption in some comparisons, while additions to usual care produced different patterns for psychosocial outcomes. Comparisons against active single-disorder cognitive-behavioral treatment did not consistently show an incremental benefit. The effects were generally small, with substantial heterogeneity. This evidence supports careful selection and measurement rather than a universal claim of superiority for every integrated package. Magill et al., 2025.

Depression and anxiety with a substance use disorder

Clinicians evaluate whether depressive or anxious symptoms are independent disorders, substance-related effects, or both. Evidence-based treatments may include disorder-specific psychotherapy, indicated medication, and addiction-focused care delivered concurrently. Integrated CBT can identify cycles in which dysphoria, anticipated relief, use, rebound symptoms, and avoidance reinforce each other; it can also teach alternative behaviors, social problem-solving, and strategies for high-risk contexts. Research outcomes depend on depression severity, substance type, treatment comparator, and whether the study measures symptoms, abstinence, or both. The connected anxiety-specific mechanisms are examined in Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity.

A program treating only the substance-related behavior may leave a persistent mood or anxiety disorder undertreated. Equally, treating only the mood symptoms may overlook withdrawal, overdose exposure, and severe compulsive use. Reliable improvement in one domain can support progress in the other, but clinicians monitor both outcomes rather than assuming that both will resolve simultaneously.

PTSD and substance use disorder

Concurrent treatment has particularly important disorder-specific evidence for PTSD and substance use disorder. Trauma-focused psychotherapies such as prolonged exposure or cognitive processing therapy can be offered with addiction treatment when clinically appropriate and delivered by trained clinicians. A mandatory prolonged abstinence interval before evidence-based PTSD treatment is not generally supported by contemporary VA guidance. Integrated protocols such as Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure, commonly called COPE, directly combine trauma-focused treatment with substance-use interventions. VA National Center for PTSD.

Project Harmony, a 2024 systematic review and network meta-analysis, found that integrated trauma-focused therapies were more effective at reducing PTSD symptoms than several non-trauma-focused or substance-focused comparators, although designs, outcome timing, and the available evidence differ. PTSD improvement should not be equated automatically with equivalent improvements in all substance-use outcomes. Clinicians consider current instability, acute safety, patient consent, and capacity to participate while preserving access to indicated treatment. Hien et al., 2024; VA PTSD and substance use guidance.

Bipolar disorder and substance use disorder

Comorbid bipolar disorder creates additional requirements for mania recognition, longitudinal mood charting, medication continuity, and attention to sleep, impulsivity, and stimulant or alcohol exposure. Integrated group therapy and adapted cognitive-behavioral models have been studied, but individual trials are small, and no specific combined psychotherapy has shown uniform effects on both bipolar and substance-use outcomes. A 2024 review of randomized trials concludes that treatment should be personalized and multimodal. O'Hearn et al., 2024.

Mania, mixed states, or severe depression may require urgent psychiatric stabilization. In less acute phases, plans can combine disorder-specific pharmacotherapy, addiction interventions, psychoeducation, relapse-risk monitoring, and interpersonal support. A treatment team must not interpret a transient improvement in use as evidence that maintenance treatment for bipolar disorder is no longer required.

Schizophrenia-spectrum illness and substance use disorder

Care for a person with psychosis and substance use disorder may combine antipsychotic treatment, substance-focused therapies, outreach, housing support, physical-health monitoring, family involvement where desired, and assertive community services when indicated. NICE recommends that people with coexisting psychosis and substance use have access to both kinds of treatment, typically through mental health services with specialist substance input and accountable care coordination. NICE CG120; NICE NG58.

The evidence base for particular psychosocial additions remains complex. A Cochrane review of 41 randomized trials involving 4,024 participants found no high-quality evidence that one psychosocial approach consistently outperformed standard care for important outcomes in populations with severe mental illness and substance misuse; interpretation was restricted by heterogeneity, bias, and incomplete outcomes. Professional recommendations for integrated and continuous services draw on clinical need, service access, and the broader evidence as well as this uncertain comparative intervention evidence. Hunt et al., 2019. The disorder-specific clinical discussion is found in Schizophrenia and Substance Use Disorders: Dual-Diagnosis Care.

Harm Reduction, Crisis Prevention, and Recovery Support

Integrated services incorporate harm reduction into ordinary clinical care. This may include overdose education, access to naloxone, infectious disease prevention, safer-use counseling, safer-prescribing practices, vaccination or testing when appropriate, and a practical plan to obtain urgent medical help. Services should also address injury, driving and occupational risk, vulnerable relationships, and possible exploitation. The aim is to prevent avoidable harms and keep access to treatment open while working toward the person's broader goals. Harm reduction does not replace evidence-based treatment for a diagnosed disorder. SAMHSA TIP 42; CDC OUD guidance.

A safety plan should specify how clinicians and the person will respond to worsening depression, suicidal thoughts, emerging psychosis, mania, increased substance exposure, missed medication, withdrawal symptoms, or overdose. It identifies clinical and personal supports and emergency pathways. Care teams should reassess suicide risk when clinical circumstances change and should not assume that either psychiatric or addiction treatment alone covers the full risk profile. Access to emergency services is warranted when immediate safety cannot be maintained.

Recovery includes symptoms and behaviors as well as functioning and a sustainable life structure. Outcomes may encompass fewer overdose events, safer use, reduction or cessation of particular substances, psychiatric symptom remission, meaningful relationships, stable housing, participation in education or work, and patient-defined well-being. These outcomes can follow different trajectories. A return to substance use or psychiatric symptom recurrence calls for assessment, treatment adaptation, and renewed support rather than automatic discharge from care.

Care coordination across settings

An effective system clarifies roles among primary care, psychiatry, addiction medicine, nursing, psychotherapy, emergency departments, peer services, and social care. A warm referral includes an appointment and responsibility for follow-up rather than simply a list of telephone numbers. Shared information is exchanged under applicable confidentiality and consent rules. Care plans should document medication reconciliation, safety considerations, follow-up dates, and transitions from inpatient to outpatient services. NICE describes coordination, housing and social support as essential components of care for people with severe mental illness and coexisting substance problems. NICE NG58.

At transition points, the person may face decreased opioid tolerance, gaps in psychiatric medicines, loss of accommodation, or separation from established clinicians. Discharge planning therefore starts before discharge, includes access to necessary medications and follow-up care, and pays attention to the elevated overdose danger associated with return to opioid use after reduced tolerance. The appropriate intensity of outpatient, residential, monitored, or hospital care reflects acute risks and multidimensional treatment needs, not a fixed label applied to everyone with two diagnoses. See Addiction Severity and Level of Care: How Treatment Needs Are Assessed.

Choosing the Appropriate Level and Model of Care

Outpatient integrated treatment may be suitable when safety is manageable, the person can engage in planned follow-up, and medical or psychiatric symptoms can be monitored in the community. Intensive outpatient or day treatment may provide additional structure without a residential admission. Residential care can address situations requiring sustained support or a safer environment, while inpatient medical or psychiatric care addresses acute medical danger, severe withdrawal, or psychiatric emergencies. Care level should be revised in response to risk, functioning, available supports, and response to treatment.

For people with repeated crises, serious psychotic illness, unstable housing, or difficulty keeping appointments, assertive outreach and intensive case management may improve contact and continuity. The exact benefit of a branded integrated model cannot be presumed from its label; teams should examine staff competencies, access to appropriate medications, actual coordination, and patient-centered outcomes. The SAMHSA treatment models chapter distinguishes service settings, integrated interventions, and the resources required to implement them. SAMHSA TIP 42, Chapter 7.

How to recognize a genuinely integrated service

A service can explain who evaluates both conditions, which psychiatric and addiction treatments it offers directly, how outside specialists are coordinated, how medication interactions are reviewed, how urgent situations are handled, and how patients are contacted after a lapse in attendance. It uses a shared care plan with explicit goals in both domains and can describe follow-up after hospitalization or withdrawal management. It communicates respectfully, makes services accessible, and allows the person's preferences to shape choices consistent with safety.

Warning signs of fragmented care include requiring a person to resolve all substance problems before receiving assessment for severe psychiatric symptoms, denying addiction treatment solely because of mental illness, inconsistent prescribing across teams, or discharge without continuity after an acute episode. These barriers are specifically addressed by NICE coexisting severe mental illness guidance.

Special Clinical Populations and Contexts

Adolescents and emerging adults

Young people need developmental and family-context assessment, careful attention to confidentiality and consent, evaluation of school and peer functioning, and appropriate assessment for emerging psychiatric illness. Substance use can affect sleep, learning, impulse control, and family relationships during development. Treatment must use age-appropriate, evidence-based interventions and distinguish experimental approaches from established care. Youth with psychosis and substance misuse should have access to suitable specialist assessment rather than being passed between systems. NICE CG120.

Pregnancy and the postpartum period

Care during pregnancy involves obstetric and perinatal mental health teams alongside addiction specialists where indicated. Treatment decisions account for maternal health, fetal considerations, medication risks and benefits, withdrawal hazards, violence exposure, and postpartum continuity. An untreated serious psychiatric or substance use disorder can itself create substantial risk. Pregnant patients with opioid use disorder require clinician-guided evidence-based care; abrupt medication discontinuation or unmonitored withdrawal should not be recommended through general educational material. Nonstigmatizing, confidential engagement supports the likelihood of receiving care.

Older adults, chronic illness, and multiple medications

In older adults, intoxication, withdrawal, depressive symptoms, cognitive impairment, falls, pain, and prescribed sedatives can overlap. Physical frailty, renal or hepatic function, and complex medication schedules influence treatment. Clinicians should screen carefully for medical causes of behavioral changes and reconcile prescription, over-the-counter, and nonprescribed substances. Coordination with primary care, caregivers with permission, and relevant specialists is particularly important.

Housing instability, justice involvement, and inequity

A person with unstable housing may find it impossible to follow a plan built around frequent appointments, refrigeration, reliable transport, or a private telephone. Justice involvement can interrupt treatment, prescriptions, and follow-up, while release can be a high-risk transition. Adaptations may include outreach, housing coordination, flexible scheduling, access to insurance or benefits assistance, and direct linkage with community services. Clinicians should recognize discrimination, stigma, cultural differences, language access, and the possibility that treatment policies themselves contribute to disengagement. SAMHSA TIP 42, Chapter 6; NICE NG58.

Measuring Treatment Outcomes and Reassessing the Plan

Evaluation needs measures in both disorders and in everyday functioning. Substance outcomes include frequency and pattern of use, toxic events, abstinence or reduction when appropriate, use of medications for substance use disorder, emergency visits, and retention in care. Mental health outcomes include structured symptom assessments, clinical episodes, self-harm risk, functioning, medication effects, and patient-reported quality of life. A single negative urine test, one symptom questionnaire, or a brief period without substance use cannot summarize the trajectory of both conditions.

Clinicians should consider whether an observed symptom change reflects intervention effects, reduced substance exposure, natural symptom fluctuation, medication changes, contextual improvement, or regression to the mean. A strong treatment evaluation distinguishes the outcomes important to the person from surrogate measures and documents the timing of change. Apparent improvement requires careful interpretation when only people who remain in treatment are measured; high dropout can bias conclusions about effectiveness.

The plan is revised when symptoms persist, the person develops adverse effects, substance use returns, housing is lost, or an intervention becomes inaccessible. Multiple pathways can produce meaningful recovery. Continued treatment may include psychiatric maintenance care, substance-specific medication, psychotherapy, peer and family support, and practical assistance. A person can improve substantially in functioning while still requiring long-term treatment for one or both disorders.

What the Scientific Evidence Establishes—and What Remains Uncertain

Established practice includes screening for the other disorder, providing indicated treatment for each confirmed condition, assessing shared safety risks, avoiding exclusion solely because of co-occurrence, and coordinating care across clinicians and settings. These recommendations are supported by major health system guidance, clinical rationale, and disorder-specific efficacy evidence. Integrated service design also responds to the documented harms of fragmented and inaccessible care. SAMHSA TIP 42; NICE NG58.

Evidence of incremental effectiveness for a specific integrated psychotherapy is more conditional. The 2019 Cochrane review of 41 trials in severe mental illness found low-quality or very-low-quality evidence for many contrasts and could not establish one clearly superior psychosocial approach. The 2025 meta-analysis of 47 cognitive-behavioral trials detected modest improvements that depended on the comparator and selected outcomes. These conclusions address distinct populations and interventions, so neither directly overturns the other. Hunt et al., 2019; Magill et al., 2025.

A comparatively stronger disorder-specific signal supports trauma-focused concurrent or integrated psychotherapy for PTSD and a substance use disorder, particularly improvement in PTSD symptoms. Bipolar and substance use interventions remain more limited and individualized; severe mental illness trials often have important design limitations. Evidence on service-level costs, comparative effectiveness, long-term quality of life, and which patients benefit most from particular integration formats is incomplete. Hien et al., 2024; O'Hearn et al., 2024.

Research design challenges

Studies differ in whether they require formal diagnoses, allow polysubstance use, include people with acute suicidality or unstable housing, and measure abstinence, consumption, mental symptoms, retention, or functioning. Active control treatments may themselves provide high-quality integrated elements, narrowing measured between-group effects. Treatment fidelity, staff training, and access to medication vary across systems. Follow-up losses can obscure outcomes. These factors limit simple statements that an intervention works for every combination of disorders. A scientifically responsible interpretation specifies the tested population, comparison, outcome, and evidence certainty.

Integrated Treatment in Digital and Artificial Environments

Telehealth, electronic referral systems, shared care plans, and digital symptom tracking can support communication and access when privacy, accessibility, and clinical oversight are adequately addressed. A clinically evaluated digital therapeutic intervention is a specific regulated or studied intervention; a general chatbot, an AI companion, or an unvalidated mental health app is a different class of product. Evidence for professional psychiatric or addiction treatment cannot be transferred automatically to conversational software. High-risk features such as psychosis, overdose, suicidal intent, or medically dangerous withdrawal require established clinical and emergency pathways. This distinction matters within Psychology for the Artificial Era as digital mediation becomes an increasing part of access to care.

Digital tools may improve appointment reminders, patient education, or monitoring, but access inequalities, inaccurate advice, data privacy, and automated responses to crises require independent evaluation. For clinical decisions, the accountable treatment relationship remains with qualified professionals and the health system. Any future claim of effectiveness for a particular application should rest on comparative outcomes, validated safety procedures, and transparency about the target population.

Practical Questions About Integrated Treatment

Can depression or PTSD be treated while a person is still using substances?

Yes, when the patient is appropriately assessed and acute safety issues are addressed, treatment for depression or PTSD can occur while substance use disorder care continues. Substance use may complicate diagnosis, engagement, and some medications, yet a blanket requirement to complete prolonged abstinence before any psychiatric care can postpone clinically indicated treatment. The appropriate intervention and timing depend on symptom severity, intoxication or withdrawal risk, other medical conditions, and the patient's preferences. Trauma-focused concurrent treatment has meaningful evidence in PTSD and substance use disorder. VA National Center for PTSD.

Is dual diagnosis a separate disease?

Dual diagnosis is a common clinical expression for the co-occurrence of at least one substance use disorder and one mental disorder. Each established disorder retains its own diagnostic criteria. The clinical value of the term is to signal that assessments, treatment decisions, and risk management must take both conditions into account. The term co-occurring disorders is often clearer because more than two diagnoses may be involved.

Does every patient need one therapist for both disorders?

No. Fully integrated treatment in one clinical team is one organizational arrangement. Concurrent disorder-specific therapies can also serve the patient when clinicians coordinate medication, safety, goals, and monitoring. The appropriate model depends on local availability, complexity, specialist expertise, patient preference, and the actual quality of coordination. SAMHSA co-occurring disorder care models.

Is detoxification sufficient if mental illness is also being treated?

Withdrawal management addresses an acute physiological syndrome and its immediate complications. Long-term treatment of substance use disorder may require medication, behavioral treatment, risk reduction, and ongoing recovery support. Co-occurring psychiatric illness has its own treatment needs. A safe withdrawal episode therefore forms one potential component of a larger plan, not its endpoint. SAMHSA TIP 42.

What if both disorders worsen at once?

The team reassesses immediate medical and psychiatric safety, current intoxication or withdrawal, prescribed and nonprescribed medicines, suicide risk, available support, and appropriate level of care. Acute life-threatening states require emergency services. After stabilization, the treatment plan should be revised jointly rather than treating the event as evidence that continued care is futile.

How long does integrated treatment last?

Duration depends on the disorders, their severity, responses to specific treatments, and functional needs. Some structured therapies last a defined number of sessions, while psychiatric maintenance medication, medications for opioid use disorder, and recovery support may continue much longer. Longitudinal reassessment determines which components remain useful. Recovery and remission evolve on individual timelines.

Conclusion

Integrated treatment is an accountable way to care for two interacting clinical conditions. It begins with reliable assessment, treats confirmed mental and substance use disorders according to their own evidence bases, coordinates decisions across clinicians, anticipates shared safety risks, and maintains continuity through setbacks and life transitions. The strongest practice is specific: match the intervention to the diagnoses, measure meaningful outcomes in both domains, support patient participation, and distinguish established guideline recommendations from uncertain incremental effects of particular treatment packages. Continuity, competent treatment, and attention to functioning make integration real for the person receiving care.

Related Articles

• Substance Use Disorders and Addiction Recovery — Scientific Research Cluster — the published central scientific chapter.

• Addiction Severity and Level of Care: How Treatment Needs Are Assessed — multidisciplinary evaluation and matching care intensity.

• Alcohol Use Disorder: Signs, Diagnosis, and Treatment — alcohol-specific diagnosis and evidence-based care.

• Opioid Use Disorder: Symptoms, Risks, and Treatment — opioid-specific medical care and overdose risk.

• Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — the established anxiety-specific canonical article.

• Schizophrenia and Substance Use Disorders: Dual-Diagnosis Care — psychosis-spectrum clinical care.

• Substance-Induced Psychosis: Causes, Symptoms, and Treatment — diagnosis and treatment of substance-induced psychosis.

References

American Society of Addiction Medicine. (2020). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. Journal of Addiction Medicine. https://doi.org/10.1097/ADM.0000000000000633.

American Society of Addiction Medicine and American Academy of Addiction Psychiatry. (2024). The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. https://pmc.ncbi.nlm.nih.gov/articles/PMC11105801/.

Centers for Disease Control and Prevention. (2024). Opioid use disorder: Treating. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html.

Hien, D. A., Papini, S., Saavedra, L. M., et al. (2024). Project Harmony: A systematic review and network meta-analysis of psychotherapy and pharmacologic trials for comorbid posttraumatic stress, alcohol, and other drug use disorders. Psychological Bulletin, 150(3), 319–353. https://doi.org/10.1037/bul0000409.

Hunt, G. E., Siegfried, N., Morley, K., Brooke-Sumner, C., and Cleary, M. (2019). Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews, CD001088. https://doi.org/10.1002/14651858.CD001088.pub4.

Magill, M., Helminen, E. C., Lynch-Gadaleta, B., Allen, K., Kiluk, B. D., and Ray, L. A. (2025). Cognitive-behavioral interventions for co-occurring substance use and mental health disorders: A meta-analysis of consumption and psychosocial functioning. Drug and Alcohol Dependence, 274, 112756. https://doi.org/10.1016/j.drugalcdep.2025.112756.

National Institute on Alcohol Abuse and Alcoholism. (n.d.). Treatment for alcohol problems: Finding and getting help. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/treatment-alcohol-problems-finding-and-getting-help.

National Institute for Health and Care Excellence. (2011). Coexisting severe mental illness (psychosis) and substance misuse: Assessment and management in healthcare settings (CG120). https://www.nice.org.uk/guidance/cg120/chapter/Recommendations.

National Institute for Health and Care Excellence. (2016). Coexisting severe mental illness and substance misuse: Community health and social care services (NG58). https://www.nice.org.uk/guidance/ng58/chapter/recommendations.

O'Hearn, B., Akpolat, N., Kobaissi, H., et al. (2024). Psychosocial and psychopharmacological interventions for comorbid bipolar disorder and substance use disorders: A review. Psychiatric Annals, 54(9), e258–e262. https://doi.org/10.3928/00485713-20240918-01.

Substance Abuse and Mental Health Services Administration. (2020). Substance use disorder treatment for people with co-occurring disorders (Treatment Improvement Protocol 42, updated edition). https://www.ncbi.nlm.nih.gov/books/NBK571020/.

Substance Abuse and Mental Health Services Administration. (2024). Advisory: Substance use disorder treatment for people with co-occurring disorders (based on TIP 42). https://www.samhsa.gov/resource/ebp/advisory-substance-use-disorder-treatment-people-co-occurring-disorders-based-tip-42.

Substance Abuse and Mental Health Services Administration. (n.d.). Managing life with co-occurring disorders. https://www.samhsa.gov/mental-health/serious-mental-illness/co-occurring-disorders.

U.S. Department of Veterans Affairs, National Center for PTSD. (n.d.). Treatment of co-occurring PTSD and substance use disorder in VA. https://www.ptsd.va.gov/professional/treat/cooccurring/tx_sud_va.asp.